AFM
NVIV

Anson Funds Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Anson Funds Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-73
Closed -$93K – 30
2018
Q2 		$93K Buy
+73
New +$401K 0.05% 22

Other funds holding NVIV

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Anson Funds Management's NVIV Position: Q3 2018 in Review

Anson Funds Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2018, closing a stake of 73 shares — an estimated $93K sold.

Anson Funds Management first reported a position in NVIV in Q2 2018 and held it in 1 quarter. The position peaked at $93K in Q2 2018. 15 funds tracked by Wall St. Rank hold NVIV as of Q3 2018.

  • Anson Funds Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2018 after selling out during the quarter.
  • Anson Funds Management sold 73 InVivo Therapeutics Holdings Corp shares in Q3 2018, an estimated $93K.
  • Anson Funds Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2018 and held it in 1 quarter.
  • Anson Funds Management's InVivo Therapeutics Holdings Corp position peaked at $93K in Q2 2018.
  • 15 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2018.

Based on Anson Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.